{
    "symbol": "EMBC",
    "quarter": 4,
    "year": 2022,
    "date": "2022-12-20 13:26:02",
    "content": " The year-over-year decrease of approximately $114 million is primarily due to the reduction in gross profit dollars that I just referred to, the incurrence of separation and standup expenses related to Embecta becoming its own publicly traded company, interest expense that was incurred in the fourth quarter of fiscal 2022 as compared to $0 in the prior year period, as well as a non-cash impairment charge of $58.9 million associated with the decision to abandon certain manufacturing production lines in the United States and $5.5 million of costs incurred related to purchase commitments which was also related to the decision to abandon those same manufacturing production lines."
}